Research programme: coronavirus vaccines - Novavax

Drug Profile

Research programme: coronavirus vaccines - Novavax

Alternative Names: MERS vaccine - Novavax; Middle East Respiratory Syndrome Coronavirus (MERS-CoV) vaccine - Novavax

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novavax
  • Class Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Middle East respiratory syndrome coronavirus
  • Discontinued Severe acute respiratory syndrome

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Middle-East-respiratory-syndrome-coronavirus(Prevention) in USA
  • 30 Apr 2014 Final immunogenicity data from a preclinical trial in Middle East respiratory syndrome (MERS-CoV) and Severe acute respiratory syndrome (SARS) coronavirus infections released by Novavax
  • 06 Jun 2013 Preclinical trials in prevention of Coronavirus (Middle East Respiratory Syndrome) infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top